Need clarity on disposal and return process for cut medicine strips and surgical products: Bangalore Chemists' Association
The CDSCO's guidance document is aimed at addressing issues emerging from the careless disposal of unused or expired medicines and the hazards it creates in the environment and public health. The document is expected to help various stakeholders, including the general public, to dispose of expired or unused medicine in a safe manner, and is also an important move towards curbing the growth of antimicrobial resistance (AMR).
Rajeev Singh Raghuvanshi, Drugs Controller General (India), in a communication dated May 25 to the Drugs Controllers of all States and Union Territories, called on them to encourage the stakeholders concerned in their respective States to adopt the guidelines for safe disposal of expired/unused drugs which will be an important step in combating AMR in the country.
The guidance document analyses various methods, including landfill after encapsulation or inertisation of drugs, use of sewer, burning in open containers, medium temperature incineration, novel high temperature incineration, and chemical decomposition. Examining the existing rule position, it details the procedures to be followed by stakeholders for the disposal of such drugs at each level.
Need clarity
'Upon reviewing the guidance document, we have identified several areas that require clarification and necessary ratification to ensure the successful and practical implementation of the disposal framework,' said BDCDA president B. Thirunavukkarasu.
'We need clarity on the disposal and return process for cut strips of medicines, for Propaganda-cum-Distribution (PCD) medicines, expired generics where high-trade margins are cited, and expired surgical products such as gloves and syringes. Currently, these are disposed of just like any other trash in the dustbin,' Mr. Thirunavukkarasu said.
Elaborating on the operational challenges from a retailer's perspective, he said there is a need to align with the industry practice of 150 days for return of expired medicines presently followed owing to the MoU signed between National Trade body and the pharma companies or provide a flexible period of 60 to 90 days. 'Common batch number mismatches owing to fragmented supply chains must be resolved to avoid denial of returns,' he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
5 hours ago
- Mint
Shresth: New national index to boost drug safety across India
New Delhi: The Union health ministry has launched the State Health Regulatory Excellence Index (Shresth) to benchmark and strengthen the systems that regulate drugs in states through a transparent, data-driven framework. The health of all citizens begins with the safety, quality, and effectiveness of the medicines they take, and ensuring their quality is a commitment of the government to every person in India, said Punya Salila Srivastava, Union health secretary in on Tuesday. The Shresth initiative, proposed by the Central Drugs Standard Control Organization (CDSCO), aims to improve the performance of state drug regulatory authorities nationwide, guaranteeing that drug safety and quality standards are consistently met. During a virtual meeting with health secretaries and drug controllers from various states and Union territories, Srivastava described Shresth as a virtual tool for states to assess their current position and work toward a "maturity certification". She emphasized the crucial role played by states and Union territories in ensuring quality manufacturing and distribution in India and the need to recognize and support their best practices. The new index will enable targeted improvements in human resources, infrastructure, and digitization across states, ensuring drug safety is guaranteed for every Indian, regardless of where they live. The states will be divided into two categories: 'manufacturing states' and primarily distribution states/UTs', and will be ranked accordingly. Manufacturing states will be evaluated on 27 indices across five key areas: human resources, infrastructure, licensing activities, surveillance activities, and responsiveness. Primarily distribution states will be evaluated on 23 indices. The data for the predefined metrics will be submitted by states to the CDSCO by the 25th of each month, with the scores being calculated and shared with all states and union territories on the 1st of the following month. Dr. Rajeev Singh Raghuvanshi, the Drug Controller General of India, said this index will help to harmonize regulatory processes across the country. It will also promote cross-learning of best practices and a collaborative spirit among states. The CDSCO will facilitate the sharing of success stories from top-performing states to encourage collaboration and the transfer of knowledge. Representatives from the states pointed out that Shresth is not just a scorecard but a roadmap for states to ensure safe and effective drugs and medical devices. They also noted that a uniform implementation of the Drugs and Cosmetics Act, along with the sharing of best practices and a structured knowledge-sharing platform, will help ensure that all states have a functional regulatory system. Srivastava also highlighted India's achievement of WHO maturity level-3 status for vaccines, stressing that the next step is to elevate medicines to the same global standard, reinforcing India's role as the 'pharmacy of the world'. Mint on 9 February reported that about the government's plan on developing drug regulatory index.
News18
16 hours ago
- News18
What It Takes to Build an FDA-Approved Oncology Plant in India
The strategic, operational, and compliance playbook behind India's growing footprint in regulated cancer drug markets. India's pharmaceutical industry has earned its place as the world's largest supplier of generic medicines, with over 650 manufacturing facilities approved by the US FDA. This number positions India as the global custodian in generics. While this statistic is often cited to highlight scale, a more telling sign of maturity is the rising number of oncology plants built in India, not just to serve domestic markets but to meet the stringent regulatory standards of the US and EU. Among all drug categories, oncology manufacturing demands the most rigorous quality controls, cleanroom architecture, and data integrity systems. Building such a facility isn't a matter of scaling up what already exists. It's a fundamental shift in how a company thinks, plans, executes, and sustains compliance. The difference begins with the product itself. Oncology drugs, especially those based on highly potent APIs, cytotoxics, or monoclonal antibodies, require full containment, sophisticated air-handling systems, and precise zone separation. Even minor lapses in cross-contamination or validation can result in patient harm. Unlike standard oral generics, oncology formulations often involve sterile injectables, lyophilised powders, or targeted biologics. Each step in the process, from material handling to packaging, must be validated against international GMP standards. They must undergo installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) validation and continuous environmental monitoring. These aren't mere upgrades to existing facilities. They are entirely new ecosystems built from the ground up. The journey of getting FDA Approval begins long before a brick is laid. The process begins with site selection. This plays a critical role, especially when waste handling and zoning compliance for hazardous materials are involved. Pharma hubs in Gujarat, Baddi, Telangana, and Maharashtra offer infrastructural advantages, but even here, environmental clearance, utility design, and HVAC zoning take months to finalise. The regulatory approvals run in parallel. Companies need to secure a state manufacturing license, followed by CDSCO approval and eventually, US FDA registration. In parallel, the design and construction teams work closely with quality and validation teams to establish protocols for cleanroom classification, air change rates, and water-for-injection (WFI) systems. Once construction is complete, validation begins with processes like IQ, OQ and PQ being run across all systems from HVAC to filling lines, and every deviation is documented and closed. This phase alone can stretch over six to nine months. In total, it can take two to three years from planning to inspection. This integrated effort demands not just technical competence but cultural alignment. Companies that invest early in staff training, data integrity systems, and audit simulations are typically better prepared for FDA scrutiny. Those that delay often face the issuance of Form 483, an inspectional observation report listing any conditions that may violate the Food, Drug, and Cosmetic Act. These findings range from incomplete batch records to deficiencies in aseptic processing and signal gaps in quality systems. As global inspections ramped up in recent times, foreign FDA drug inspections more than doubled from 130 in FY2021 to 262 in FY2022, where OAI outcomes have steadily declined, reflecting better inspection readiness and improved documentation culture. The returns, however, justify the effort. Once approved, the facility gives huge access to the US and European markets, where oncology drugs represent one of the fastest-growing therapeutic segments. Mr. Vishwa Savla, the Managing Director and CEO of Pinnacle Life Science, which got US FDA Approval last year, said in this context, 'We knew from the beginning that if we got this right, it would change the trajectory of our company. Of course, it's a high-stakes investment, but the payoff is clear. My team was sure that this would take time, but we knew that we were building our capability for a lifetime once the facility was operational. And it's needless to emphasise that if you're serious about oncology, you have to build to FDA standards. There's no shortcut to that. The oncology pipeline demands long-term thinking, and FDA approval gave us a foothold in markets where both quality and trust are non-negotiable." Ultimately, building an FDA‑licensed oncology plant in India demands capital, time, technical rigour, and cultural commitment. But with global oncology spending expected to exceed USD 375 billion by 2027, Indian companies that invest in compliance today are positioning themselves for long-term value not just commercially, but in terms of credibility and global impact. (Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 12, 2025, 12:00 IST News agency-feeds What It Takes to Build an FDA-Approved Oncology Plant in India Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hans India
2 days ago
- Hans India
Cigarettes, bidis, chewable tobacco continue to silently raise cancer risks in youth: Experts
New Delhi: More than the new and trendy alternatives, traditional tobacco products like cigarettes, bidis, and chewable tobacco are posing a silent crisis for India's youth, significantly raising the risk of cancers like lung, mouth and throat, said health experts on Monday, calling out the need to step up the fight against these to push the fight against tobacco. According to the 2019 Global Youth Tobacco Survey, 8.5 per cent of students aged 13-15 use tobacco, contributing to 1.3 million deaths annually. With tobacco linked to 90 per cent of lung cancer cases, the experts warned that this overlooked epidemic demands immediate action beyond the vaping debate. 'Over 90 per cent of lung cancer cases in India are linked to combustible tobacco. In my clinical experience, I regularly treat patients as young as 17 for tobacco-induced complications. What we need is a calibrated approach that combines prevention, regulation, and public awareness -- not selective panic,' Dr. Narender Saini, Chairman, Antimicrobial Resistance (AMR) Standing Committee, at Indian Medical Association (IMA), told IANS. There is growing concern in the medical community that public discourse on youth addiction is missing the mark. While focus has been on new trends, the experts warned that the silent epidemic of oral and throat cancer among under-25s, linked to traditional tobacco products like gutkha and khaini, is a more urgent and dangerously overlooked crisis. 'The data points to a stark reality -- traditional tobacco's grip on our youth far outweighs other concerns, urging us to rethink our priorities. Our focus must expand from trendy alternatives to the proven killers: cigarettes, bidis, and chewable tobacco,' Dr Chandrakant S Pandav, Padma Shri Awardee, and former Prof and HoD, Community Medicine, AIIMS, New Delhi, told IANS. The global health expert noted that the traditional tobacco landscape remains largely unchallenged in schools and villages. Despite soaring concerns over vaping, combustible and smokeless tobacco products continue to thrive, fuelled by cultural acceptance and unchecked distribution. 'Tobacco use poses immediate and long-term risks to infection control. My clinical experience reveals a stark contrast: tobacco-related illnesses are rampant, while vaping-related lung issues are remarkably rare,' Saini said. The experts called for strengthening school-based interventions, community awareness campaigns, and stricter enforcement of existing laws. 'Bridging the gap between data and policy, stakeholders must now craft a unified strategy that tackles both supply and demand, ensuring young Indians are shielded from every form of tobacco harm,' Pandav added. Dr. Pawan Gupta, Senior Consultant, Pulmonary Medicine at a leading city-based hospital, told IANS that 'the damage inflicted by traditional tobacco begins early and lasts a lifetime". 'We witness its devastating consequences daily -- oral cancers, lung diseases, and heart conditions -- often in individuals who started using these products in their teenage years. With 1.35 million deaths annually, the science is clear: traditional tobacco is a proven killer, and our youth are its most vulnerable targets,' Gupta said.
